AZD-2014


CAS No. : 1009298-59-2

AZD-2014,1009298-59-2
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000107
Synonyms:3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide
Molecular Formula:C₂₅H₃₀N₆O₃
Molecular Weight:462.54
Target:mTOR
IC50:2.8 nM
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Yellow solid powder
Purity: > 98%
Cat No:I000107
Cas No:1009298-59-2
Product-Name:AZD-2014
InChI:InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1
InChIKey:JUSFANSTBFGBAF-IRXDYDNUSA-N
SMILES:CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C

AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ).
IC50 value: 2.8 nM
Target: mTOR
AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD2014 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.


1:Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition. Kim ST, Kim SY, Klempner SJ, Yoon J, Kim N, Ahn S, Bang H, Kim KM, Park W, Park SH, Park JO, Park YS, Lim HY, Lee SH, Park K, Kang WK, Lee J.Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. PMID: 28028034
2:AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest. Yu CC, Huang HB, Hung SK, Liao HF, Lee CC, Lin HY, Li SC, Ho HC, Hung CL, Su YC.PLoS One. 2016 Mar 31;11(3):e0151942. doi: 10.1371/journal.pone.0151942. eCollection 2016. PMID: 27031247 Free PMC Article
3:The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M.Oncotarget. 2015 Nov 10;6(35):37930-47. doi: 10.18632/oncotarget.6122. PMID: 26473447 Free PMC Article
4:A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Wimalasingham A, Burke W, Sarker SJ, Hussain S, Ralph C.Eur Urol. 2016 Mar;69(3):450-6. doi: 10.1016/j.eururo.2015.08.035. Epub 2015 Sep 11. PMID: 26364551
5:AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Guichard SM, Curwen J, Bihani T, D/'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.Mol Cancer Ther. 2015 Nov;14(11):2508-18. doi: 10.1158/1535-7163.MCT-15-0365. Epub 2015 Sep 10. PMID: 26358751 Free Article
6:First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U.Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422. Epub 2015 Mar 24. PMID: 25805799 Free PMC Article
7:Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. Liao H, Huang Y, Guo B, Liang B, Liu X, Ou H, Jiang C, Li X, Yang D.Am J Cancer Res. 2014 Dec 15;5(1):125-39. eCollection 2015. PMID: 25628925 Free PMC Article
8:The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139. Epub 2013 Dec 4. PMID: 24311635 Free PMC Article
9:Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M.Bioorg Med Chem Lett. 2013 Mar 1;23(5):1212-6. doi: 10.1016/j.bmcl.2013.01.019. Epub 2013 Jan 18. PMID: 23375793
Related Products
  • CAS No. :1223002-54-7
    Product Name:

    QL-IX-55

    Cat No: I000855 View details
  • CAS No. :1086062-66-9
    Product Name:

    GSK-2126458

    Cat No: I000371 View details
  • CAS No. :936890-98-1
    Product Name:

    OSI-027

    Cat No: I005567 View details
  • CAS No. :162635-04-3
    Product Name:

    Temsirolimus (CCI-779, Torisel)

    Cat No: I002093 View details